These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28858443)

  • 21. Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D.
    Dennehy EB; Marangell LB; Martinez J; Balasubramani GK; Wisniewski SR
    J Psychiatr Pract; 2014 May; 20(3):178-87. PubMed ID: 24847991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
    Ostergaard SD; Bech P; Trivedi MH; Wisniewski SR; Rush AJ; Fava M
    J Affect Disord; 2014 Jul; 163():18-24. PubMed ID: 24836083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    Gilmer WS; Gollan JK; Wisniewski SR; Howland RH; Trivedi MH; Miyahara S; Fleck J; Thase ME; Alpert JE; Nierenberg AA; Warden D; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1246-56. PubMed ID: 18681756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
    Sakurai H; Suzuki T; Yoshimura K; Mimura M; Uchida H
    Psychopharmacology (Berl); 2017 Aug; 234(16):2453-2461. PubMed ID: 28470399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic subgroups for citalopram response in the STAR*D trial.
    Jakubovski E; Bloch MH
    J Clin Psychiatry; 2014 Jul; 75(7):738-47. PubMed ID: 24912106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study.
    Denninger JW; van Nieuwenhuizen AO; Wisniewski SR; Luther JF; Trivedi MH; Rush AJ; Gollan JK; Pizzagalli DA; Fava M
    J Nerv Ment Dis; 2011 Oct; 199(10):807-10. PubMed ID: 21964277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder.
    Perlis RH; Uher R; Ostacher M; Goldberg JF; Trivedi MH; Rush AJ; Fava M
    Arch Gen Psychiatry; 2011 Apr; 68(4):351-60. PubMed ID: 21135313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
    Lin CH; Yen YC; Chen MC; Chen CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():93-8. PubMed ID: 23989033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    McGrath PJ; Khan AY; Trivedi MH; Stewart JW; Morris DW; Wisniewski SR; Miyahara S; Nierenberg AA; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Dec; 69(12):1847-55. PubMed ID: 19026268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning.
    Kasckow J; Lanouette N; Patterson T; Fellows I; Golshan S; Solorzano E; Zisook S
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):183-90. PubMed ID: 19711335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis.
    Rakofsky JJ; Schettler PJ; Kinkead BL; Frank E; Judd LL; Kupfer DJ; Rush AJ; Thase ME; Yonkers KA; Rapaport MH
    J Clin Psychiatry; 2013 Nov; 74(11):1084-91. PubMed ID: 24330894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
    Lavretsky H; Reinlieb M; St Cyr N; Siddarth P; Ercoli LM; Senturk D
    Am J Psychiatry; 2015 Jun; 172(6):561-9. PubMed ID: 25677354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Family history of depression and therapeutic outcome: findings from STAR*D.
    Husain MM; Rush AJ; Wisniewski SR; McClintock SM; Fava M; Nierenberg AA; Davis L; Balasubramani GK; Young E; Albala AA; Trivedi MH
    J Clin Psychiatry; 2009 Feb; 70(2):185-95. PubMed ID: 19192454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
    Davis LL; Wisniewski SR; Howland RH; Trivedi MH; Husain MM; Fava M; McGrath PJ; Balasubramani GK; Warden D; Rush AJ
    Drug Alcohol Depend; 2010 Mar; 107(2-3):161-70. PubMed ID: 19945804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population.
    Kamat SA; Rajagopalan K; Pethick N; Willey V; Bullano M; Hassan M
    J Manag Care Pharm; 2008 Sep; 14(7):631-42. PubMed ID: 18774873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
    Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.